Treatment News : HPV Vaccine Works Well in HIV-Positive Women

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 28, 2014

HPV Vaccine Works Well in HIV-Positive Women

HIV-Positive women respond well to the human papillomavirus (HPV) vaccine, even when they have a low CD4 count, The New York Times reports. The AIDS Clinical Trials Group Protocol 5240 study investigated the safety of and immune system response to the vaccine Gardasil in 315 women with HIV who were between ages 13 and 45 and living in the United States, Brazil and South Africa. The researchers published their findings in Clinical Infectious Diseases.

The women were dived into three groups according to their CD4 count: Group A had counts above 350, group B between 200 and 350 and group C below 200.

After following the women for 28 weeks, the investigators found that they developed a protective immune response to each of the four strains of HPV against which Gardasil protects at a rate exceeding 70 percent, which was the preset benchmark for success. Those in group A developed antibodies against HPV types 6, 11, 16 and 18 in a respective 96 percent, 98 percent, 99 percent and 91 percent of participants. Those in group B had respective response rates of 100 percent, 98 percent, 98 percent and 85 percent. And those in group C had respective response rates of 84 percent, 92 percent, 93 percent and 75 percent.

While those with lower CD4s did respond less well to Gardasil, the researchers concluded that the vaccine would still be worthwhile for them. Furthermore, while some of the women had already been exposed to at least one of the four strains of HPV included in the vaccine’s realm of protection, only 4 percent had been exposed to all four. Consequently, there is likely still a benefit to vaccinating older, sexually active women living with HIV.

The study did not measure the vaccine’s efficacy in preventing cancer. The vaccine did, however, prove safe.

To read a release on the study, click here.

To read the study abstract, click here.

To read the Times story, click here.

Search: HPV, human papillomavirus, vaccine, Gardasil, AIDS Clinical Trials Group, HIV, Clinical Infectious Diseases.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    july8th69
    brooklyn
    New York


    OahuAJ
    Turlock
    California


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.